The tie up allows Hemispherx to manufacture and supply Alferon N Injection to physicians and patients by using Armada’s national network of specialty pharmacies.
Additionally, BioRidge Pharma (BRP) will warehouse, ship, and distribute Alferon N Injection on an exclusive basis for US markets.
Hemispherx Operations senior vice president Wayne Springate said the company is upgrading its manufacturing facility in New Brunswick, New Jersey, to include a high volume, bioreactor to manufacture Alferon N Injection.